Pediatric heart transplant (HTx) volume continues to increase with 444 transplants performed across 59 different US centers in 2016 (based on Organ Procurement and Transplantation Network (OPTN) data as of May 2017). However, even large pediatric HTx centers have relatively small patient numbers, making robust clinical research challenging. This has increasingly led to the use of clinical registry data and multicenter initiatives in pediatric HTx research.
Numerous large databases are now available that can be leveraged to study pediatric heart failure and HTx [1] [2] [3] including a variety of clinical registries, administrative databases, and research datasets. 2 While usage of such resources has provided critical insight into pediatric HTx care, each database has inherent limitations. 1, 4 Linking databases provides an opportunity to leverage the strengths of each database and to expand the possible analyses that can be performed.
This strategy has been effectively utilized across multiple disciplines including congenital heart disease and congenital heart surgery, 4 ,5 pediatric oncology, 6, 7 and organ transplantation. 8, 9 Pasquali et al successfully linked the Society of Thoracic Surgeons Congenital Heart Surgery (STS-CHS) Database and The Pediatric Health Information System (PHIS) administrative database. 4 This effort provided critical insight into resource utilization and helped to examine cost-quality relationships in the surgical repair of congenital heart disease. [10] [11] [12] Similarly, we aimed to link a robust administrative dataset in the PHIS database with the clinical depth of the Scientific Registry of Transplant Recipients (SRTR) database to more closely assess relationships between clinical predictors and resource utilization in pediatric HTx. This report documents the results of the linkage between the PHIS and SRTR databases and provides preliminary data regarding resource utilization in pediatric HTx recipients.
Methods
This study used data from the SRTR. The SRTR data system includes data on all donor, wait-listed candidates, and transplant recipients in the United States, submitted by the members of the OPTN, and has been described elsewhere. The Health Resources and Services Administration (HRSA), US Department of Health and Human Services provides oversight to the activities of the OPTN and SRTR contractors. The SRTR collects and maintains data regarding organ transplantation in the United States. Data are derived from multiple sources including the OPTN, transplant programs, organ procurement organizations, histocompatibility laboratories, the Centers for Medicare and Medicaid Services (CMS), and the National Technical Information Service's (NTIS) Death Master File. The SRTR database includes data from every organ transplant and waitlist addition within the United States since October 1987.
The PHIS database is an administrative database that collects clinical and daily resource utilization data for hospital encounters from 49 tertiary care children's hospitals. This includes data from inpatient hospitalizations, observation, ambulatory surgery, and emergency department visits. This database accumulates encounter-level diagnosis and procedural ICD-9 and ICD-10 codes, payer information, along with encounter-level hospital charge and cost data.
The PHIS and SRTR databases were linked at the patient level using indirect identifiers in a stepwise approach. The SRTR database records were limited to transplants that overlapped with data available in the PHIS database (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) . PHIS transplant encounters were identified using the All-Patient Refined Diagnosis Related Group (3 M Health Information Systems; APR-DRG) code for heart and/or lung transplantation (APR-DRG 002). Linkage of PHIS encounters with SRTR data was performed in a three-step process; (1) Uniquely linked patients were identified by matching hospital, date of birth, sex, and date of transplant, (2) unlinked records were then matched by hospital, date of birth, and sex, and (3) all remaining unlinked records were matched using hospital and date of birth. Patients with records that were unable to be uniquely linked between databases were excluded from the linked cohort, but included in a separate cohort to compare characteristics between linked and unlinked patients. Characteristics of linked and unlinked patients were compared using the χ 2 test.
A validation cohort was constructed using patients from Vanderbilt University Medical Center. Medical record numbers from the linked database were cross-validated against center data to assess accuracy of the data linkage. Further validation using patients from other centers was not possible given data restrictions.
From the linked database, all patients with complete cost and resource utilization data were identified. PHIS reports hospital charges and these were converted to costs using hospital-specific cost-to-charge ratios. All costs were adjusted for inflation to 2016 dollars using the medical component of the Consumer Price Index. Costs were assessed for the entire transplant hospitalization and also for the post-HTx period (day prior to HTx to the day of initial discharge). Costs were compared across patient-specific variables using the Kruskal-Wallis test. Total and post-HTx costs were also assessed based on areas of spending including pharmacy, laboratory, imaging, supply, clinical, and other costs. All statistical analyses were performed in SAS version 9. 
Results
A total of 3493 unique HTx hospitalizations were identified during a time when hospital-specific data was available in PHIS (1999-2016); comprising 29 different pediatric HTx centers. Demographics were unavailable for one patient and this record was excluded. Additionally, there was insufficient data to successfully link patients transplanted between 1999 and 2001, and this group was excluded. There was no other impact of year of transplant on data availability for linkage, leaving 3188 records for patients transplanted 2002-2016 available for linkage. Of these patients, 3057 (95.9%) were uniquely linked to SRTR records using the three-step algorithm, including 2896 (90.8%) with complete cost/charge data ( Figure) . Of the linked patients with available cost information, N99% were linked on all indirect identifiers (hospital, date of birth, sex, and date of transplant) with only 11 (0.4%) patients linked on subsequent merge attempts.
Demographics of patients with available cost data are shown in Table I , compared to unlinked patients and those with incomplete cost information (N = 292). There were significant differences between patients included and not included in the cost analysis in terms of diagnosis, listing status at the time of HTx (1A, 1B, or status 2), and the need for ECMO, ventilator, or inotropic support at the time of HTx. Notably, unlinked patients were more commonly retransplants and appeared to be a sicker population with a higher frequency of patients requiring ECMO, ventilator support, inotropic support, and being listed UNOS status 1A at the time of HTx.
A total of 142 (4.6% of the linked cohort) patients from our center were present in the linked group and included in the validation cohort. Cross-validation using medical record numbers was performed. In this group, we determined that 100% of the patients were true matches, with no incorrectly linked patients.
The median transplant hospitalization cost across all centers was $518,906 (IQR $324,199-$889,738) with a m e d i a n p o s t -H T x c o s t o f $ 3 3 4 , 4 9 0 ( I Q R $235,506-$498,803). As shown in Table II , there was significant variation in total HTx hospitalization cost based on patient age, diagnosis, race, blood type, listing status at the time of HTx, and the need for ECMO, VAD, ventilator, or inotropic support at the time of HTx. Similarly, there was significant variation in post-HTx cost based on patient age, diagnosis, race, listing status at the time of HTx, and the need for ECMO, ventilator, or inotropic support at the time of HTx. Younger patients experienced higher costs compared to older patients, with patients b1 year of age comprising the group with the highest relative cost (median cost: hospitalization $703,897; post-HTx $386,020). Patients with a diagnosis of congenital heart disease had higher total and post-HTx costs compared to those with diagnoses of cardiomyopathy or retransplantation. Additionally, patients with blood type O experienced higher total HTx hospitalization cost, but blood type did not significantly impact post-HTx costs.
Cost breakdown based on area of spending is shown in Table III 
Discussion
This analysis demonstrates the feasibility and potential utility of a linkage between the SRTR and PHIS databases. Using indirect identifiers, a robust linkage was created with the vast majority of patients matching all identifiers. Although our validation cohort was relatively small, 100% of the linked patients were correctly matched across databases, demonstrating that the linkage algorithm is valid and the resulting dataset accurately captures the population of interest. This finding is comparable to prior linkage studies, which have demonstrated that linkage using indirect identifiers is accurate and reliable. 4, 5, 7 This unique linked database expands analytic possibilities and will help to further pediatric HTx research, in particular with regard to resource utilization.
The merger of these databases capitalizes on the strengths of each database and expands the potential analyses that can be performed. The PHIS database provides an excellent platform to assess estimated costs and associated resource utilization across large children's hospitals. In addition to this, it provides a high level of data granularity through the documentation of diagnosis and procedure codes. However, PHIS only captures data from hospital encounters and thus lacks long-term outcome data. The SRTR database provides much more transplant specific details that are not captured in PHIS (eg, listing status). Importantly, SRTR data better captures the longitudinal experience of a transplant candidate/ recipient with respect to infections, rejection, and graft/ patient survival, regardless of whether these events were associated with a hospital encounter. The increased data granularity provided by the merger of these two databases is particularly useful in pediatric heart disease where the population and diagnoses are extremely heterogeneous; severely limiting the ability of either database in isolation to capture the full spectrum of disease.
Overall, our linkage was successful, with greater than 95% of patients being uniquely matched and 90.8% available for analysis of costs and resource utilization. It is notable that some differences were detected between linked patients with cost data and unlinked patients or those with incomplete cost information. The unlinked group appears sicker with a greater requirement for 1A listing status, ECMO, ventilator support, and inotropic support. The etiology for these differences is unclear, but is likely multifactorial. Additionally, a disproportionate number of unlinked patients were retransplants. This is likely the result of there being multiple transplant encounters for a single patient, resulting in duplicate records that impaired successful linkage. The differences noted between patients included and not included in the cost analyses may impact the generalizability of our preliminary findings and potentially result in underestimation of costs; however, use of severity-adjusted cost models will help to minimize this limitation. Preliminary cost data from this project clearly demonstrates the advantages and potential utility of this unique linked database in the assessment of resource utilization. 14 Our analysis provides more contemporary cost data for pediatric HTx and represents the largest US sample reported to date. The inclusion of multiple centers in our database is advantageous, as the results are more representative of the costs and population at US pediatric HTx centers. Additionally, it is important to note that in the study by Dayton et al., cost effectiveness was assessed using graft longevity derived from published data, and was not patient specific. 13 A similar approach has been utilized in other cost-effectiveness studies, 15 but has inherent limitations. The linked PHIS-SRTR database provides an added advantage of linking resource utilization with patient-specific long-term outcomes, which may improve our ability to conduct a robust analysis of cost-effectiveness. Further analysis of this database is needed with the development of cost models to adjust for individual patient characteristics, and will aid in assessing the drivers of cost in this population. Our analysis demonstrates that there are multiple factors that are associated with higher total HTx hospitalization and post-HTx hospital costs in the pediatric population. Not surprisingly, patients b1 year of age and those with a diagnosis of congenital heart disease represent groups with the highest total and post-HTx costs. The use of mechanical circulatory support (MCS) also increases costs. We anticipate this unique dataset will improve assessment of the impact of evolving MCS strategies on resource utilization. Patients with blood type O demonstrated increased total HTx hospital cost, but similar post-HTx costs. We hypothesize that this finding is secondary to longer waitlist times in this group due to increased competition for blood type O donors. Importantly, recent changes in pediatric donor allocation policies may help to minimize the impact of recipient blood type on HTx cost, and could be the focus of future study.
In addition to providing a platform to assess resource utilization, the merger of SRTR and PHIS greatly increases data granularity. This allows analyses to be completed that were not feasible with either database in isolation. In particular, this allows analysis of subpopulations of pediatric HTx recipients that would otherwise not be possible (eg, Down syndrome). It may also improve assessment of practice variation and help to identify optimal management strategies through the linkage of patient-specific variables with long-term outcomes.
This project has inherent limitations. Our linkage was performed only for transplanted patients as the date of transplant provides a discreet identifier that facilitated the successful linkage. Therefore, the current linked database excludes patients who were listed but not transplanted. Future linkage of this group may be possible, but will require an updated linking strategy. Additionally, as with any large database, there is the potential for missing or erroneous data. While this limitation remains, we believe that the successful merger of these databases will help to minimize the degree of missing data and allow cross-verification between databases. Lastly, professional fees are not included in the PHIS database and may result in underestimation of costs.
This project demonstrates the successful merger of a clinical registry database and an administrative database using indirect identifiers. This linkage will allow an in depth assessment of resource utilization in pediatric HTx and represents the largest reported US cohort to date. This linkage will also provide a platform to expand analytic possibilities in pediatric HTx research to assess practice variation and address subpopulations that otherwise would not be possible.
